Artelo Biosciences Book Value Per Share Growth & History (ARTL)
Artelo Biosciences's book value per share was -$1.89 for fiscal 2025.
View full Artelo Biosciences company overviewArtelo Biosciences annual book value per share history
| Fiscal year | Period ended | Book value per share | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | -$1.89 | -$16.99 | — |
| 2024 | 2024-12-31 | $15.10 | $4.05 | +36.59% |
| 2023 | 2023-12-31 | $11.06 | -$9.33 | −45.76% |
| 2022 | 2022-12-31 | $20.38 | -$8.52 | −29.47% |
| 2021 · Dec 31 | 2021-12-31 | $28.90 | — | — |
| 2021 · Aug 31 | 2021-08-31 | $0.02 | -$34.91 | −99.94% |
| 2020 | 2020-08-31 | $34.93 | -$38.33 | −52.32% |
| 2019 | 2019-08-31 | $73.26 | $76.73 | — |
| 2018 | 2018-08-31 | -$3.47 | -$20.79 | — |
| 2017 | 2017-08-31 | $17.32 | $17.97 | — |
| 2016 | 2016-08-31 | -$0.65 | -$1.40 | — |
| 2015 | 2015-08-31 | $0.75 | -$0.14 | −15.29% |
| 2014 | 2014-08-31 | $0.88 | — | — |
Artelo Biosciences quarterly book value per share
| Fiscal quarter | Period ended | Book value per share | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $7.42 | $13.41 | — |
| Q1 2026 | 2026-03-31 | $9.91 | $9.32 | +1562.94% |
| Q4 2025 | 2025-12-31 | -$1.89 | -$16.99 | — |
| Q3 2025 | 2025-09-30 | -$1.22 | -$7.13 | — |
| Q2 2025 | 2025-06-30 | -$5.99 | -$12.77 | — |
| Q1 2025 | 2025-03-31 | $0.60 | -$8.27 | −93.27% |
| Q4 2024 | 2024-12-31 | $15.10 | $4.05 | +36.59% |
| Q3 2024 | 2024-09-30 | $5.91 | -$7.92 | −57.25% |
| Q2 2024 | 2024-06-30 | $6.78 | -$10.31 | −60.30% |
| Q1 2024 | 2024-03-31 | $8.86 | -$9.67 | −52.16% |
| Q4 2023 | 2023-12-31 | $11.06 | -$9.33 | −45.76% |
| Q3 2023 | 2023-09-30 | $13.83 | -$9.18 | −39.90% |
| Q2 2023 | 2023-06-30 | $17.09 | -$8.09 | −32.14% |
| Q1 2023 | 2023-03-31 | $18.53 | -$8.90 | −32.44% |
| Q4 2022 | 2022-12-31 | $20.38 | -$8.52 | −29.47% |
| Q3 2022 | 2022-09-30 | $23.01 | — | — |
| Q2 2022 | 2022-06-30 | $25.18 | — | — |
| Q1 2022 · Mar 31 | 2022-03-31 | $27.42 | — | — |
| Q4 2021 · Dec 31 | 2021-12-31 | $28.90 | — | — |
| Q1 2022 · Nov 30 | 2021-11-30 | $30.09 | $3.13 | +11.61% |
| Q4 2021 · Aug 31 | 2021-08-31 | $0.02 | -$34.91 | −99.94% |
| Q3 2021 | 2021-05-31 | $23.16 | -$15.71 | −40.41% |
| Q2 2021 | 2021-02-28 | $26.04 | -$22.64 | −46.51% |
| Q1 2021 | 2020-11-30 | $26.96 | -$38.23 | −58.64% |
| Q4 2020 | 2020-08-31 | $34.93 | -$38.33 | −52.32% |
| Q3 2020 | 2020-05-31 | $38.87 | $35.99 | +1250.62% |
| Q2 2020 | 2020-02-29 | $48.68 | $64.58 | — |
| Q1 2020 | 2019-11-30 | $65.19 | $77.21 | — |
| Q4 2019 | 2019-08-31 | $73.26 | $76.73 | — |
| Q3 2019 | 2019-05-31 | $2.88 | $5.45 | — |
| Q2 2019 | 2019-02-28 | -$15.89 | -$22.16 | — |
| Q1 2019 | 2018-11-30 | -$12.02 | -$21.34 | — |
| Q4 2018 | 2018-08-31 | -$3.47 | -$20.79 | — |
| Q3 2018 | 2018-05-31 | -$2.57 | $1.61 | — |
| Q2 2018 | 2018-02-28 | $6.26 | $7.18 | — |
| Q1 2018 | 2017-11-30 | $9.32 | $9.63 | — |
| Q4 2017 | 2017-08-31 | $17.32 | $17.97 | — |
| Q3 2017 | 2017-05-31 | -$4.19 | -$3.74 | — |
| Q2 2017 | 2017-02-28 | -$0.92 | -$0.71 | — |
| Q1 2017 | 2016-11-30 | -$0.30 | -$0.34 | — |
| Q4 2016 | 2016-08-31 | -$0.65 | -$1.40 | — |
| Q3 2016 | 2016-05-31 | -$0.45 | -$1.11 | — |
| Q2 2016 | 2016-02-29 | -$0.21 | -$0.60 | — |
| Q1 2016 | 2015-11-30 | $0.03 | — | — |
| Q4 2015 | 2015-08-31 | $0.75 | -$0.14 | −15.29% |
| Q3 2015 | 2015-05-31 | $0.66 | — | — |
| Q2 2015 | 2015-02-28 | $0.39 | — | — |
| Q4 2014 | 2014-08-31 | $0.88 | — | — |
Artelo Biosciences book value per share trends
Between the periods ended 2014-08-31 and 2025-12-31, Artelo Biosciences's book value per share decreased from $0.88 to -$1.89, a change of -$2.77. The latest reported quarter, Q2 2026, shows $7.42.
What book value per share means
Book value per share estimates the common shareholders’ accounting equity represented by each share. It can help compare a company’s balance-sheet value over time, although market value can differ substantially from book value.
How book value per share is calculated
TickerStat calculates book value per share as SEC-reported common shareholders’ equity divided by reported period-end common shares. Preferred equity is subtracted when separately reported, and basic weighted-average shares are used only when period-end shares are unavailable. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Artelo Biosciences source filings ↗